Journal of Biopharmaceutical Statistics

Papers
(The TQCC of Journal of Biopharmaceutical Statistics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data38
The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring27
Incorporating propensity scores for evidence synthesis under bayesian framework: review and recommendations for clinical studies13
Multiplicity issues for platform trials with a shared control arm13
Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials12
The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations10
Propensity score-integrated power prior approach for augmenting the control arm of a randomized controlled trial by incorporating multiple external data sources9
A BAYESIAN ADAPTIVE TWO-STAGE DESIGN FOR PEDIATRIC CLINICAL TRIALS9
Log-rank tests for censored clustered data under generalized randomized block design: Saddlepoint approximation9
TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy9
Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study9
Leverage multiple real-world data sources in single-arm medical device clinical studies9
The use of the win odds in the design of non-inferiority clinical trials9
Conditional borrowing external data to establish a hybrid control arm in randomized clinical trials8
Using supervised machine learning approach to predict treatment outcomes of vedolizumab in ulcerative colitis patients8
Weighted log-rank tests for left-truncated data under Wei’s urn design: saddlepoint p-values and confidence intervals7
Evaluating bias control strategies in observational studies using frequentist model averaging7
A simulation study of approaches for handling disease progression in dose-finding clinical trials7
A novel approach to augment single-arm clinical studies with real-world data7
Futility stopping in clinical trials, optimality and practical considerations7
Matching design for augmenting the control arm of a randomized controlled trial using real-world data7
Dose-finding design and benchmark for a right censored endpoint6
Confidence intervals for the Youden index and its optimal cut-off point in the presence of covariates6
Dynamic borrowing from a single prior data source using the conditional power prior6
Restricted mean survival time and confidence intervals by empirical likelihood ratio6
Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer5
Tests for equivalence of two survival functions: alternatives to the PH and PO models5
Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses5
Propensity score-integrated approach to survival analysis: leveraging external evidence in single-arm studies5
Bayesian joint modeling for partially linear mixed-effects quantile regression of longitudinal and time-to-event data with limit of detection, covariate measurement errors and skewness5
Statistical and practical considerations in designing of immuno-oncology trials5
Evaluation of diagnostic tests for low prevalence diseases: a statistical approach for leveraging real-world data to accelerate the study5
Bayesian sample size determination in a three-arm non-inferiority trial with binary endpoints5
The win odds: statistical inference and regression4
Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials4
Randomized two-stage optimal design for interval-censored data4
Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials4
Analysis of time-to-event data using a flexible mixture model under a constraint of proportional hazards4
P-values and confidence intervals of linear rank tests for left-truncated data under truncated binomial design4
Evidence inconsistency degrees of freedom in Bayesian network meta-analysis4
Flexible parametric accelerated failure time model4
Matching within a hybrid RCT/RWD: framework on associated causal estimands4
Two-tailed asymptotic inferences for the odds ratio in cross-sectional studies: evaluation of fifteen old and new methods of inference4
Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials4
Power priors with entropy balancing weights in data augmentation of partially controlled randomized trials4
A new basket trial design based on clustering of homogeneous subpopulations4
Multi-stage adaptive enrichment trial design with subgroup estimation4
Evaluating medical device adverse event signals using a likelihood ratio test method4
Sample size determination for Bayesian analysis of small n sequential, multiple assignment, randomized trials (snSMARTs) with three agents3
Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study3
Defective 3-parameter Gompertz model with frailty term for estimating cure fraction in survival data3
Inferential properties with a novel two parameter Poisson generalized Lindley distribution with regression and application to INAR(1) process3
Confidence intervals of mean residual life function in length-biased sampling based on modified empirical likelihood3
Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpoints3
Joint comparison of the predictive values of multiple binary diagnostic tests: an extension of McNemar’s test3
Pair copula construction for longitudinal data with zero-inflated power series marginal distributions3
Perspectives on informative Bayesian methods in pediatrics3
Practical guidance on modeling choices for the virtual twins method3
In vitro dissolution profile comparison using bootstrap bias corrected similarity factor, f 23
Challenges and potential strategies utilizing external data for efficacy evaluation in small-sized clinical trials3
A collection of parametric modal regression models for bounded data3
A year in review: artificial intelligence permeates into mainstream statistics in pharmaceutical product development at a laggard pace3
Power calculations for the sequential parallel comparison design with continuous outcomes3
Analysis and reporting of pediatric growth and development assessment from clinical trials: overview and challenges3
A nonparametric approach to confidence intervals for concordance index and difference between correlated indices3
On dependence assumption in p-value based multiple test procedures3
Assessing model accuracy using random data split: a simulation study2
Adaptive platform trials: the impact of common controls on type one error and power2
Nonparametric inference of the area under ROC curve under two-phase cluster sampling2
A Cholesky-based sparse covariance estimation with an application to genes data2
Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL)2
Estimand in benefit-risk assessment2
Optimal sample size determination for single-arm trials in pediatric and rare populations with Bayesian borrowing2
Modelling non-linear patterns of time-varying intervention effects on recurrent events in infectious disease prevention studies2
Application of a likelihood ratio test based method for safety signal detection to left ventricular assist devices2
Retrieved-Dropout-Based multiple imputation for time-to-event data in cardiovascular outcome trials2
Recommended confidence intervals for the conditional odds ratio in matched-pairs designs2
Comparison of statistical methodologies used to estimate the treatment effect on time-to-event outcomes in observational studies2
A stochastically curtailed single‐arm phase II trial design for binary outcomes2
Survival stacking with multiple data types using pseudo-observation-based-AUC loss2
PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints2
Fast QLB algorithm and hypothesis tests in logistic model for ophthalmologic bilateral correlated data2
Case study using RWD in the context of a pivotal trial for regulatory approval in a rare disease2
Inclusion of unexposed subjects improves the precision and power of self-controlled case series method2
Dynamic incorporation of real world evidence within the framework of adaptive design2
A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data2
Testing the homogeneity of proportions for combined unilateral and bilateral data2
How to select the initial dose for a pediatric study?2
Estimation on conditional restricted mean survival time with counting process2
Design of paediatric trials with benefit-risk endpoints using a composite score of adverse events of interest (AEI) and win-statistics2
Addressing statistical issues when leveraging external control data in pediatric clinical trials using Bayesian dynamic borrowing2
Forecasting determinants of recurrence in lung cancer patients exploiting various machine learning models2
A structured framework for adaptively incorporating external evidence in sequentially monitored clinical trials2
Weighted log-rank tests for censored data under Wei’s urn design: saddlepoint approximation and confidence intervals2
Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights2
Adjusted win ratio using the inverse probability of treatment weighting2
Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform2
Investigation of the relationship between heart rate and functional class in pulmonary hypertension2
Two-stage response adaptive randomization designs for multi-arm trials with binary outcome2
Using surrogate information to improve confirmatory platform trial with sample size re-estimation2
Randomization tests in clinical trials with multiple imputation for handling missing data2
Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment2
Equivalence tests under the Cox-Aalen model and the partly Aalen model2
A win ratio approach for comparing crossing survival curves in clinical trials2
Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users2
Rectangular multivariate normal prediction regions for setting reference regions in laboratory medicine2
Imputation of Missing Covariates in Randomized Controlled Trials with Continuous Outcomes: Simple, Unbiased and Efficient Methods2
The Joint i3+3 (Ji3+3) design for phase I/II adoptive cell therapy clinical trials2
Clinical trial considerations for pediatric cancer drug development2
Estimands and estimators of two-level methods using return to baseline strategy for longitudinal clinical trials with incomplete daily patient reported outcomes2
Calibrated dynamic borrowing using capping priors2
Parameter estimation of Weibull distribution for the number of days between drug administration and early onset adverse event2
0.037911176681519